MedTrace Logo

A Study to Investigate the Mass Balance of BTD-001

NCT03107013 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-10-24

No results posted yet for this study

Summary

This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.

Conditions

  • Molecular Mechanisms of Pharmacological Action

Interventions

DRUG

[14C]-BTD-001

Carbon-14 labeled BTD-001

Sponsors & Collaborators

  • Balance Therapeutics

    lead INDUSTRY

Principal Investigators

  • Nand Signh, MD · Quotient Clinical Ltd

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-03
Primary Completion
2017-05-01
Completion
2017-05-01
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03107013 on ClinicalTrials.gov